C2 STRATEGIES lobbying for BC3 TECHNOLOGIES INC.

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 17, 2026

Income

$10,000

What the client paid this registrant for the period.

Client based in

Maryland

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Homeland Security

Federal support for fielding FDA cleared hemostatic wound care technology for military and first responder use. Matters relating to combat casualty care and prehospital hemorrhage control, including Department of Defense medical materiel and Defense Health Agency programs.

Budget/Appropriations

Federal support for fielding FDA cleared hemostatic wound care technology for military and first responder use. Matters relating to combat casualty care and prehospital hemorrhage control, including Department of Defense medical materiel and Defense Health Agency programs.

Defense

Federal support for fielding FDA cleared hemostatic wound care technology for military and first responder use. Matters relating to combat casualty care and prehospital hemorrhage control, including Department of Defense medical materiel and Defense Health Agency programs.

Health Issues

Federal support for fielding FDA cleared hemostatic wound care technology for military and first responder use. Matters relating to combat casualty care and prehospital hemorrhage control, including Department of Defense medical materiel and Defense Health Agency programs.